univers coverag
calendar event
clinic confer societi inherit metabol disord societi toxicolog
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medacorp call reinforc view potenti delay fremanezumab
ev/ebitda multipl
bottom line spoke medacorp current good manufactur practic cgmp
specialist regard fda warn letter outstand celltrion manufactur site
incheon south korea produc activ pharmaceut ingredi api teva
fremanezumab anti-calcitonin gene-rel peptid cgrp monoclon antibodi current
fda review prophylact migrain treatment specialist believ
inspect result warn letter done fill/finish part
facil mani observ cite particularli around data integr could present
api manufactur part facil well specialist believ long teva
continu sourc fremanezumab api celltrion facil outstand warn
letter unlik fda approv product teva state plan anoth
api supplier fremanezumab appear near-term option believ
success resolut warn letter would allow fremanezumab approv reflect
analysi specialist view believ given sever issu cite
take longer end manag initi timelin estim close warn letter
thu push back launch time fremanezumab earli
maintain pt rate
also updat model last publish version februari
includ takeaway cgmp specialist call pp celltrion facil pp
new model pp
elagolix succe ph profil confirm larg de-risk
bottom line morn mp report posit result second phase studi
elagolix uterin fibroid uf appear confirm evid efficaci
prior posit phase studi indic increas confid current revenu
forecast product expect launch first endometriosi follow uf
achiev revenu data studi elari uf-ii prior phase
studi elari uf-i support regulatori submiss elagolix uterin fibroid
second product two indic expect present addit data studi
upcom medic meet top-lin data look good appear support elagolix
efficaci uf full data may help differenti elagolix gnrh agonist-bas
medicin alter investor view futur competit landscap categori
current forecast gross sale elagolix risk-adjust model use
probabl approv uterin fibroid probabl approv endometriosi
consensu estim
second phase studi support elagolix uterin fibroid
elagolix safeti profil reportedli similar studi though detail disclos
rova-t triniti studi readout next major valid mileston
concern adcom off-cycl launch price stock
discount rate termin growth rate
bottom line share pull back ahead nda submiss month ali
refractori nontubercul mycobacterium lung infect ntm caus mycobacterium avium
complex believ stock weak driven investor angst
anticip advisori committe adcom panel summer headwind off-cycl launch
medicar although except usual volatil expect
adcom product launch expect compani fare well believ investor fear
provid attract buy opportun reiter op
believ ali efficacy/safeti data serv well adcom although stock may rang
bound actual vote occur could volatil biotech stock often fda brief
document post on-line
believ below-consensu estim achiev sell side estim need
come order incorpor manag messag headwind off-cycl launch
medicar
result analysi adjust revenu estim reflect off-cycl medicar
bottom line morn report fy oper result provid
updat key tazemetostat program in-lin disclosur recent investor event
compani report revenu oper expens moder
consensu estim result ep loss per share manag
team narrow time initi nda file epithelioid sarcoma es year
reiter intent file snda follicular lymphoma fl clear
believ pathway acceler approv tazemetostat follicular lymphoma although
mani question remain efficaci tazemetostat monotherapi dlbcl
expect busi year clinic data readout includ initi mesothelioma data mid-year
updat data present on-going nhl trial second half major medic meet
increment updat confirm timelin reassur
mesothelioma longer durat nhl data offer near term upsid
plan share addit data on-going tazemetostat nhl studi
last updat icml june
ad mesothelioma forecast increas epithelioid reduc dlbcl
price boost result lower tax outer year
revenu mm ep
aet sharehold approv deal
bottom line aet sharehold approv deal morn approxim
vote cast share outstand vote favor deal
op share vote favor deal doj sent second request deal await
anti-trust clearanc like challeng anoth larg albeit vertic deal ci
op -esrx mp hopper
achondroplasia adcom may shed posit vosoritid prospect
bottom line public comment made avail ahead march pediatr
advisori committe pac endocrinolog metabol drug advisori committe
emdac meet fda consid evid requir approv
achondroplasia treatment like vosoritid panelist discuss evid requir
 infant toddler and/or older children adolesc endpoint
clinic meaning impact patient function psycholog well-b reiter op
make equiti invest full servic pbm rxadvanc
bottom line initi invest full servic pbm rxadvanc continu reinforc
integr medic pharmaci benefit invest expect synergist
acaria specialti rx asset within servic platform envolv term
transact disclos though right expand equiti invest
chang manag rxadvanc rxadvanc leverag trademark cloud platform
collabor pbm cloud provid servic health plan aco employ state medicaid
program invest rxadvanc come recent announc acquisit mhm servic
mm parent cash end estim
parent cash end exclud acquisit fide transact remain controversi
uncertainti around probabl time close exhibit
bottom line announc today fda agre propos content time
roll nda submiss lead product lumateperon manag continu
target complet submiss process although lumateperon data packag
mix rel optimist approv given believ differenti safeti
profil fda preced area regulatori flexibl file treatment
schizophrenia base mix data packag far posit phase ii posit phase
second phase drug effect separ placebo even though activ control
risperidon separ lumateperon nda accept expect pdufa date
seem like given compani announc today seem like advisori
committe meet discuss applic late earli date like
rel optimist panel like vote approv probabl first cycl
approv sinc efficaci demonstr two tradit design randomized-control trial
furthermor lumateperon safeti profil seem meaning differenti current
avail antipsychot still confer burdensom side effect current assum odd
approv model
bottom line announc organiz chang morn larri renfro current
vice-chair ceo optum lead enterprise-wid growth effort serv
manag optum ventur sir andrew witti current independ member
bod former ceo glaxo smithklin mp appoint new ceo optum
chang take effect juli
cardiolog medacorp physician perspect
golo- casi- may nearer think pt
full data preclin result support synthet biotic
backlog growth signific resist downgrad mp post
tx chip rural hidalgo area rfp award offer optim tx
expect submit new drug applic nda ali march prioriti
previous guid remain track expect advisori committe meet
adcom amikacin liposom inhal suspens ali refractori nontubercul
mycobacteri lung infect ntm caus mycobacterium avium complex
stock come investor question efficaci long-term durabl
approv believ fda panelist could view posit
extens studi data refractori ntm patient favor
believ discuss point may even consid possibl ali front-lin
therapi ahead guidelin base therapi fda-approv
addit ali data american thorac societi meet may
top-lin result etrasimod ph ii ulcer coliti uc studi expect
recent fda refus file rtf letter rival celg op ozanimod like put
greater investor regul emphasi scrutini etrasimod safeti profil
thu etrasimod show favor pk/pd safeti profil rel
ozanimod relief among investor could lead higher valu etrasimod uc
one numer potenti autoimmun indic drug target
although management elabor specif indic management believ gastrointestin
gi liver indic particularli interest
project peak etrasimod uc sale addit smaller indic
 primari biliari cholang pyoderma gangrenosum
extraintestin manifest associ inflammatori bowel diseas
ph ii data crohn diseas pain
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
april pdufa rubraca ovarian cancer
rubraca saw slow launch result competit posit platinum-
rubraca first parp inhibitor us approv line set brca patient
howev product tsro zejula azn mp lynparza surpass us
approv earlier broader line mainten set pressur rubraca
demand line
us approv rubraca broad line mainten indic pdufa date april
import growth driver product competit profil accord
physician survey
continu believ parp inhibitor address potenti larg market
opportun across sever tumor type beyond ovarian cancer among prostat
cancer repres particularli attract opportun pivot trial
well underway interim data expect
april arql arq ph ia data btk inhibitor
compani arq inhibit wild-typ mutat btk
known resist mechan ibrutinib
on-going ph ia dose-escal phase enrol patient b-cell malign
includ b-cell lymphoma chronic lymphocyt leukemia cll waldenstrom
macroglobulinemia refractori therapeut option includ ibrutinib
initi ph ia data primarili safeti pk/pd pharmacokinetics/pharmacodynam
expect year american associ cancer research annual
among arql asset remain intrigu view given potenti
differenti gen btk inhibitor
arq ph ib data respons rate safeti endometri cancer also plan
aacr year
april -nk ph data aml proc solid tumor
donor-deriv adopt memori natur killer nk cell therapi current
voyag trial patient refractori relaps acut myelogen leukemia
apollo studi patient platinum resist ovarian cancer proc
dimens studi patient advanc solid tumor
cell program ex vivo increas persist
prolifer anti-tumor activ
ph voyag studi aml ph apollo studi proc on-going
updat program like avail american
associ cancer research annual meet
burosumab recent receiv posit eu chmp decis x-link
hypophosphataemia xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
pdufa date fda advisori committe meet expect
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
top-lin storm ph ii data expand trial expect april
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therpay confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
amicu enzyme-chaperon candid gener promis clinic
data thu far ph i/ii studi
management recent announc studi enrol addit pt gain insight
drug clinic profil
meanwhil observ studi potenti run-
upcom ph studi could provid import natur histori compar data
on-going ph i/ii studi
amicu meet regul updat
earli specul management believ rang outcom possibl
meet remain laser-focus get fastest approv pathway
model alreadi reflect earli launch possibl ascrib probabl success
po market vs po launch
base analysi medacorp kol interview believ could
best-in-class drug post-op pain growth opportun heron fulli
appreci street view
data two ph studi expect
expect posit data ph instil studi bunionectomi hernia repair
base previou posit stat sig ph ii data medacorp kol feedback
alway inher risk ph trial upon fda request
use wwocf method -- sensit measur use ph ii
believ ph high likelihood success
addit secondari endpoint especi reduct opioid rescu medic
import potenti commerci success
believ grow risk-adjust sale driven long-
act post-op pain relief simpl conveni administr potenti
signific share orthoped procedur especi painful/costli one
follow ph also look ph iib data tka nerv block
breast augment studi
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
sourc leerink research compani inform factset price prior day
state nm award medicaid reprocur contract
fda adcom joint meet blood product microbiolog devic
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
brief document eversens pma medic devic adcom
fda adcom clinic chemistri clinic toxicolog devic panel
medic devic link note
pdufa opdivo yervoy intermedi poor risk renal cell carcinoma
fda adcom peripher central nervou system drug
fda adcom endocrinolog metabol drug
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
societi inherit metabol disord
societi toxicolog
intern confer alzheim parkinson diseas
 canadian academi patholog
intern confer ureagenesi defect
societi surgic oncolog
american academi osteopathi
societi gynecolog oncolog
intern societi amyloidosi
american colleg medic genet genom
intern societi heart lung transplant
societi american gastrointestin endoscop surgeon
american societi laser medicin surgeri
european associ studi liver
american societi cataract refract surgeri
american associ cancer research arql tsro
molecular target tripl meet aacr-nci-eortc
american head neck societi combin otolaryngolog spring meet
american societi androlog
european congress clinic microbiolog infecti diseas
american academi neurolog
nation foundat infecti diseas annual confer vaccin
american societi aesthet plastic surgeri
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut outlin possibl drug price polici
draconian fear
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
novob dc disappoint oral sema currenc price fear bake
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 respit price yet friendli hill fda
could longer term
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 news patent decis one remind method use
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
 increas pt takeda collabor stock weak offer oppti
 atop dermat still without ped leerink
dupix derm survey
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 initi
 analyst event best idea
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
biopharma atop derm still without ped leerink dupi derm
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
